We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Canakinumab (Ilaris) — anti-IL-1β monoclonal antibody
An injectable anti-interleukin-1β monoclonal antibody (Ilaris), approved for rare periodic fever syndromes. Famous for the landmark CANTOS trial — the first proof that lowering inflammation alone (without touching lipids) cuts cardiovascular events, validating the 'inflammaging' hypothesis. But CANTOS showed NO all-cause-mortality benefit and MORE fatal infections, and the follow-up cancer trials failed. An extremely expensive prescription biologic, not a supplement.
Prescription medication — not a dietary supplement
Canakinumab is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Canakinumab doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2008–2026.
Based on 146 studies · 29 meta-analyses · 66 RCTs
Confidence
High confidenceBy outcome
CANTOS is a landmark proof-of-concept — canakinumab cut recurrent cardiovascular events purely by lowering IL-1β/inflammation, independent of lipids, validating the 'inflammaging' idea — but it showed NO all-cause-mortality benefit and MORE fatal infections, the follow-up CANOPY cancer trials failed, the longevity rationale stays hypothesis-level, and it is an extremely expensive injectable biologic, not a take-able supplement.
65 randomised trials
96% were about Canakinumab in an audit of 50 of them
Every randomised or controlled trial of Canakinumab indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
15 trials ongoing or recruiting · 70 completed on ClinicalTrials.gov
44 of the completed trials have posted results
Registered trials show research momentum for Canakinumab, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Canakinumab (Ilaris) is a fully human monoclonal antibody that binds and neutralizes interleukin-1β (IL-1β), a master pro-inflammatory cytokine released by the NLRP3 inflammasome.
It is approved for rare interleukin-1-driven autoinflammatory diseases — cryopyrin-associated periodic syndromes (CAPS) and other periodic fever syndromes — where its registration trial showed it rapidly induces and maintains remission.
Its place in geroscience comes from the 'inflammaging' hypothesis: chronic, low-grade IL-1β/IL-6 inflammation is a hallmark of aging that drives atherosclerosis, frailty, and cancer.
The landmark CANTOS trial (Ridker, NEJM 2017) randomized ~10,000 post-myocardial-infarction patients with elevated hsCRP to canakinumab or placebo and found that the 150 mg dose significantly reduced recurrent cardiovascular events — crucially, with no change in LDL or other lipids.
This was the first hard-outcome proof that targeting inflammation itself, independent of cholesterol, changes cardiovascular outcomes — a genuine proof-of-concept for the inflammation theory of atherosclerosis. The honest limits are decisive, though.
CANTOS showed NO reduction in all-cause mortality, and canakinumab caused significantly MORE fatal infections than placebo — the net survival balance did not favor the drug.
An exploratory CANTOS analysis suggested lower incident and fatal lung cancer, which generated enormous excitement, but the dedicated CANOPY oncology program that followed FAILED — CANOPY-2 showed no overall-survival benefit in non-small-cell lung cancer.
And canakinumab is an extraordinarily expensive subcutaneous biologic (list price in the tens of thousands of dollars per dose), used for narrow rare-disease indications, not something a person takes for longevity.
The score reflects a genuinely field-defining demonstration that lowering inflammaging reduces cardiovascular events, set against no overall-survival benefit, a real fatal-infection signal, failed anticancer trials, hypothesis-level longevity rationale, and a cost/route that put it far outside any practical 'supplement' use.
Canakinumab is a monoclonal antibody that binds interleukin-1β and blocks it from engaging its receptor — shutting down a master pro-inflammatory cytokine.
By neutralizing IL-1β at the top of the cascade, it lowers downstream IL-6 and hsCRP — the inflammatory axis that drives atherosclerosis.
Chronic IL-1β-driven inflammation is a hallmark of aging; CANTOS tested whether lowering it — independent of cholesterol — changes hard cardiovascular outcomes.
How Canakinumab works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Higher serious-infection risk — careful screening and monitoring; the fatal-infection signal is most concerning here.
Screen and treat before starting; active infection is a contraindication.
Limited data; specialist-directed only for an approved indication — not for off-label longevity use.
Combining IL-1 blockade with other immunosuppression markedly increases serious-infection risk — generally avoided.
Live vaccines should not be given during treatment due to immunosuppression.
Tip: Most common effect of IL-1 blockade; screen for latent infection and hold dosing during active infection.
Tip: Monitor blood counts; injection-site reactions are usually mild.
Tip: CANTOS showed a real excess of fatal infection — a hard limit; promptly evaluate and treat any infection.
Canakinumab has an evidence score of 4/10 — emerging evidence based on 146 indexed studies, including 1 meta-analysis. An injectable anti-interleukin-1β monoclonal antibody (Ilaris), approved for rare periodic fever syndromes. Famous for the landmark CANTOS trial — the first proof that lowering inflammation alone (without touching lipids) cuts cardiovascular events, validating the 'inflammaging' hypothesis. But CANTOS showed NO all-cause-mortality benefit and MORE fatal infections, and the follow-up cancer trials failed. An extremely expensive prescription biologic, not a supplement. Representative study: PMID 40583093.
Dosing for Canakinumab: A prescription biologic, not self-administered for longevity. Approved CAPS dosing is 150 mg subcutaneously every 8 weeks (weight-adjusted in children). The CANTOS cardiovascular regimen was 150 mg subcutaneously every 3 months. There is NO established off-label longevity protocol, and cost is prohibitive. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Canakinumab — consistent daily use matters more than the time of day. An infrequent subcutaneous injection (every 8 weeks to 3 months) given by or under a clinician; timing of day is not a meaningful variable.
Canakinumab should be used with caution — talk to a healthcare provider before taking it. Reported side effects include serious / fatal infection, infections (including upper respiratory and injection-site), neutropenia / injection-site reactions. How often they occur is not established for all of them. Use caution if any of these apply to you: Active or chronic infection; Live vaccines during treatment; Known hypersensitivity to canakinumab.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Alpha Lipoic Acid
Likely helpsUniversal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 147 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research